Sfoglia per Autore Cavazzoni, Andrea
Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome them
2026-01-01 Pagano Mariano, Marco; Sgarilli, Enrica; Mijnlieff, Dirk; Visuvasam, Bonifiya; Blesio, Andrea; Digiacomo, Graziana; Cavazzoni, Andrea; Ferracin, Manuela; Giovannetti, Elisa
Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC
2026-01-01 Cavazzoni, A.; Pagano Mariano, M.; Palladini, A.; Digiacomo, G.; La Monica, S.; Bonelli, M.; Galetti, M.; Pace, I.; Roncarati, R.; Giovannetti, E.; Aretini, P.; Minari, R.; Treccani, M.; Pluchino, M.; Lagrasta, C.; Angelicola, S.; Mazzaschi, G.; Bordi, P.; Gelsomino, F.; Agustoni, F.; Petronini, P. G.; Tiseo, M.; Ferracin, M.; Alfieri, R.
Target validation of natural compounds: Perillaldehyde case study
2026-01-01 Blesio, A.; Giorgio, C.; Sala, S.; Cavazzoni, A.; Zanotti, I.; Tognolini, M.
Correction to: Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer (Cancers, (2020), 12, 3, (666), 10.3390/cancers12030666)
2025-01-01 Cavazzoni, A.; Digiacomo, G.; Alfieri, R.; La Monica, S.; Fumarola, C.; Galetti, M.; Bonelli, M.; Cretella, D.; Barili, V.; Zecca, A.; Giovannetti, E.; Fiorentino, M.; Tiseo, M.; Petronini, P. G.; Ardizzoni, A.
Extracellular vesicle delivery of functional extrachromosomal DNA in FGFR2-amplified cancer of unknown primary
2025-01-01 Salamon, I; Gallerani, G; Storci, G; Fontana, B; Serravalle, S; Valle, F; Brucale, M; Mariano, Mp; Cavazzoni, A; Roncarati, R; Santi, S; Bonafe, M; Ferracin, M
Novel FAK inhibitors suppress tumor growth and reverse EGFR-TKI resistance in non-small cell lung cancer
2025-01-01 Xu, Geng; Pecoraro, Camilla; Vahabi, Mahrou; Deng, Dongmei; Cavazzoni, Andrea; Fiuji, Hamid; Lagrasta, Costanza Anna Maria; Cascioferro, Stella M.; Tiseo, Marcello; Carbone, Daniela; Avan, Amir; Zucali, Paolo A.; Assaraf, Yehuda G.; Peters, Godefridus J.; Diana, Patrizia; Giovannetti, Elisa
Effects of myrtleciclib, a cyclindependent kinase inhibitor, in models of malignant pleural mesothelioma
2025-01-01 7, 5. Falcone E.; Galetti, M.; La Monica, S.; Ampollini, L.; Alfieri, R.; De Forni, D.; Poddesu, B.; Cugia, G.; Cavazzoni, A.; Cavallo, D.; Lori, F.; Petronini, P. G.; Bonelli, M.
Horizontal transfer of functional extrachromosomal DNA via extracellular vesicles in FGFR2-amplified cancer
2025-01-01 Salamon, I.; Gallerani, G.; Storci, G.; Luebeck, J.; Fontana, B.; Serravalle, S.; Valle, F.; Brucale, M.; Pagano Mariano, M.; Soru, A.; Pace, I.; Cavazzoni, A.; Roncarati, R.; Santi, S.; Bafna, V.; Bonafè, M.; Ferracin, M.
The simultaneous inhibition of PI3K and AURORA A/B pathways induced a synergistic anti-tumor effect in preclinical models of NSCLC cells carrying PI3KCA mutations
2025-01-01 Digiacomo, G.; Cavazzoni, A.; Fumarola, C.; Minari, R.; Petronini, P. G.; Alfieri, R.; Mazzaschi, G.; Tiseo, M.
Transcriptomic and functional characterization of KRASG12D and KRASG12V NSCLC clones reveals AXL as a potential target
2025-01-01 Pagano Mariano, M.; Blesio, A.; Digiacomo, G.; Mazzaschi, G.; Minari, R.; Tiseo, M.; Treccani, M.; Ferracin, M.; Petronini, P. G.; Alfieri, R.; Cavazzoni, A.
Correction to: The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells (Journal of Experimental & Clinical Cancer Research, (2018), 37, 1, (72), 10.1186/s13046-018-0741-3)
2025-01-01 Cretella, D.; Ravelli, A.; Fumarola, C.; La Monica, S.; Digiacomo, G.; Cavazzoni, A.; Alfieri, R.; Biondi, A.; Generali, D.; Bonelli, M.; Petronini, P. G.
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC)
2024-01-01 Cavazzoni, A.; Digiacomo, G.; Volta, F.; Alfieri, R.; Giovannetti, E.; Gnetti, L.; Bellini, L.; Galetti, M.; Fumarola, C.; Xu, G.; Bonelli, M.; La Monica, S.; Verze, M.; Leonetti, A.; Eltayeb, K.; D'Agnelli, S.; Moron Dalla Tor, L.; Minari, R.; Petronini, P. G.; Tiseo, M.
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341)
2024-01-01 Digiacomo, G.; Fumarola, C.; La Monica, S.; Bonelli, M.; Cavazzoni, A.; Galetti, M.; Terenziani, R.; Eltayeb, K.; Volta, F.; Zoppi, S.; Bertolini, P.; Missale, G.; Alfieri, R.; Petronini, P. G.
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments
2024-01-01 Fumarola, Claudia; La Monica, Silvia; Bonelli, Mara; Zoppi, Silvia; Alfieri, Roberta; Galetti, Maricla; Gnetti, Letizia; Campanini, Nicoletta; Pozzi, Giulia; Cavazzoni, Andrea; Mazzaschi, Giulia; Silini, Enrico Maria; Buti, Sebastiano; Petronini, Pier Giorgio
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines
2024-01-01 Eltayeb, Kamal; Alfieri, Roberta; Fumarola, Claudia; Bonelli, Mara; Galetti, Maricla; Cavazzoni, Andrea; Digiacomo, Graziana; Galvani, Francesca; Vacondio, Federica; Lodola, Alessio; Mor, Marco; Minari, Roberta; Tiseo, Marcello; La Monica, Silvia; Giorgio Petronini, Pier
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary
2024-01-01 Cavazzoni, A.; Salamon, I.; Fumarola, C.; Gallerani, G.; Laprovitera, N.; Gelsomino, F.; Riefolo, M.; Rihawi, K.; Porcellini, E.; Rossi, T.; Mazzeschi, M.; Naddeo, M.; Serravalle, S.; Broseghini, E.; Agostinis, F.; Deas, O.; Roncarati, R.; Durante, G.; Pace, I.; Lauriola, M.; Garajova, I.; Calin, G. A.; Bonafe, M.; D'Errico, A.; Petronini, P. G.; Cairo, S.; Ardizzoni, A.; Sales, G.; Ferracin, M.
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models
2024-01-01 La Monica, Silvia; Vacondio, Federica; Eltayeb, Kamal; Lodola, Alessio; Volta, Francesco; Viglioli, Martina; Ferlenghi, Francesca; Galvani, Francesca; Galetti, Maricla; Bonelli, Mara; Fumarola, Claudia; Cavazzoni, Andrea; Flammini, Lisa; Verzè, Michela; Minari, Roberta; Petronini, Pier Giorgio; Tiseo, Marcello; Mor, Marco; Alfieri, Roberta
State of the art and perspectives in pediatric hepatocellular carcinoma
2023-01-01 Digiacomo, Graziana; Serra, Roberta Pia; Turrini, Elena; Tiri, Alessandra; Cavazzoni, Andrea; Alfieri, Roberta; Bertolini, Patrizia
PD-L1 OVEREXPRESSION INDUCES ANGIOGENIC CYTOKINE SECRETION AND ENDOTHELIAL CELL MIGRATION VIA STAT SIGNALLING.
2023-01-01 Digiacomo, G.; Cavazzoni, A.; Volta, F.; Alfieri, R.; Petronini, P. G.; Tiseo, M.
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS
2023-01-01 La Monica, S.; Galetti, M.; Alfieri, R.; Cavazzoni, A.; Fumarola, C.; De Forni, D.; Lori, F.; Petronini, P. G.; Bonelli, M.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Bracing for the storm: emerging resistance mechanisms to KRAS inhibitors in pancreatic cancer and strategies to overcome them | 1-gen-2026 | Pagano Mariano, Marco; Sgarilli, Enrica; Mijnlieff, Dirk; Visuvasam, Bonifiya; Blesio, Andrea; Digiacomo, Graziana; Cavazzoni, Andrea; Ferracin, Manuela; Giovannetti, Elisa | |
| Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC | 1-gen-2026 | Cavazzoni, A.; Pagano Mariano, M.; Palladini, A.; Digiacomo, G.; La Monica, S.; Bonelli, M.; Galetti, M.; Pace, I.; Roncarati, R.; Giovannetti, E.; Aretini, P.; Minari, R.; Treccani, M.; Pluchino, M.; Lagrasta, C.; Angelicola, S.; Mazzaschi, G.; Bordi, P.; Gelsomino, F.; Agustoni, F.; Petronini, P. G.; Tiseo, M.; Ferracin, M.; Alfieri, R. | |
| Target validation of natural compounds: Perillaldehyde case study | 1-gen-2026 | Blesio, A.; Giorgio, C.; Sala, S.; Cavazzoni, A.; Zanotti, I.; Tognolini, M. | |
| Correction to: Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer (Cancers, (2020), 12, 3, (666), 10.3390/cancers12030666) | 1-gen-2025 | Cavazzoni, A.; Digiacomo, G.; Alfieri, R.; La Monica, S.; Fumarola, C.; Galetti, M.; Bonelli, M.; Cretella, D.; Barili, V.; Zecca, A.; Giovannetti, E.; Fiorentino, M.; Tiseo, M.; Petronini, P. G.; Ardizzoni, A. | |
| Extracellular vesicle delivery of functional extrachromosomal DNA in FGFR2-amplified cancer of unknown primary | 1-gen-2025 | Salamon, I; Gallerani, G; Storci, G; Fontana, B; Serravalle, S; Valle, F; Brucale, M; Mariano, Mp; Cavazzoni, A; Roncarati, R; Santi, S; Bonafe, M; Ferracin, M | |
| Novel FAK inhibitors suppress tumor growth and reverse EGFR-TKI resistance in non-small cell lung cancer | 1-gen-2025 | Xu, Geng; Pecoraro, Camilla; Vahabi, Mahrou; Deng, Dongmei; Cavazzoni, Andrea; Fiuji, Hamid; Lagrasta, Costanza Anna Maria; Cascioferro, Stella M.; Tiseo, Marcello; Carbone, Daniela; Avan, Amir; Zucali, Paolo A.; Assaraf, Yehuda G.; Peters, Godefridus J.; Diana, Patrizia; Giovannetti, Elisa | |
| Effects of myrtleciclib, a cyclindependent kinase inhibitor, in models of malignant pleural mesothelioma | 1-gen-2025 | 7, 5. Falcone E.; Galetti, M.; La Monica, S.; Ampollini, L.; Alfieri, R.; De Forni, D.; Poddesu, B.; Cugia, G.; Cavazzoni, A.; Cavallo, D.; Lori, F.; Petronini, P. G.; Bonelli, M. | |
| Horizontal transfer of functional extrachromosomal DNA via extracellular vesicles in FGFR2-amplified cancer | 1-gen-2025 | Salamon, I.; Gallerani, G.; Storci, G.; Luebeck, J.; Fontana, B.; Serravalle, S.; Valle, F.; Brucale, M.; Pagano Mariano, M.; Soru, A.; Pace, I.; Cavazzoni, A.; Roncarati, R.; Santi, S.; Bafna, V.; Bonafè, M.; Ferracin, M. | |
| The simultaneous inhibition of PI3K and AURORA A/B pathways induced a synergistic anti-tumor effect in preclinical models of NSCLC cells carrying PI3KCA mutations | 1-gen-2025 | Digiacomo, G.; Cavazzoni, A.; Fumarola, C.; Minari, R.; Petronini, P. G.; Alfieri, R.; Mazzaschi, G.; Tiseo, M. | |
| Transcriptomic and functional characterization of KRASG12D and KRASG12V NSCLC clones reveals AXL as a potential target | 1-gen-2025 | Pagano Mariano, M.; Blesio, A.; Digiacomo, G.; Mazzaschi, G.; Minari, R.; Tiseo, M.; Treccani, M.; Ferracin, M.; Petronini, P. G.; Alfieri, R.; Cavazzoni, A. | |
| Correction to: The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells (Journal of Experimental & Clinical Cancer Research, (2018), 37, 1, (72), 10.1186/s13046-018-0741-3) | 1-gen-2025 | Cretella, D.; Ravelli, A.; Fumarola, C.; La Monica, S.; Digiacomo, G.; Cavazzoni, A.; Alfieri, R.; Biondi, A.; Generali, D.; Bonelli, M.; Petronini, P. G. | |
| PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) | 1-gen-2024 | Cavazzoni, A.; Digiacomo, G.; Volta, F.; Alfieri, R.; Giovannetti, E.; Gnetti, L.; Bellini, L.; Galetti, M.; Fumarola, C.; Xu, G.; Bonelli, M.; La Monica, S.; Verze, M.; Leonetti, A.; Eltayeb, K.; D'Agnelli, S.; Moron Dalla Tor, L.; Minari, R.; Petronini, P. G.; Tiseo, M. | |
| Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) | 1-gen-2024 | Digiacomo, G.; Fumarola, C.; La Monica, S.; Bonelli, M.; Cavazzoni, A.; Galetti, M.; Terenziani, R.; Eltayeb, K.; Volta, F.; Zoppi, S.; Bertolini, P.; Missale, G.; Alfieri, R.; Petronini, P. G. | |
| Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments | 1-gen-2024 | Fumarola, Claudia; La Monica, Silvia; Bonelli, Mara; Zoppi, Silvia; Alfieri, Roberta; Galetti, Maricla; Gnetti, Letizia; Campanini, Nicoletta; Pozzi, Giulia; Cavazzoni, Andrea; Mazzaschi, Giulia; Silini, Enrico Maria; Buti, Sebastiano; Petronini, Pier Giorgio | |
| Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines | 1-gen-2024 | Eltayeb, Kamal; Alfieri, Roberta; Fumarola, Claudia; Bonelli, Mara; Galetti, Maricla; Cavazzoni, Andrea; Digiacomo, Graziana; Galvani, Francesca; Vacondio, Federica; Lodola, Alessio; Mor, Marco; Minari, Roberta; Tiseo, Marcello; La Monica, Silvia; Giorgio Petronini, Pier | |
| Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary | 1-gen-2024 | Cavazzoni, A.; Salamon, I.; Fumarola, C.; Gallerani, G.; Laprovitera, N.; Gelsomino, F.; Riefolo, M.; Rihawi, K.; Porcellini, E.; Rossi, T.; Mazzeschi, M.; Naddeo, M.; Serravalle, S.; Broseghini, E.; Agostinis, F.; Deas, O.; Roncarati, R.; Durante, G.; Pace, I.; Lauriola, M.; Garajova, I.; Calin, G. A.; Bonafe, M.; D'Errico, A.; Petronini, P. G.; Cairo, S.; Ardizzoni, A.; Sales, G.; Ferracin, M. | |
| Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models | 1-gen-2024 | La Monica, Silvia; Vacondio, Federica; Eltayeb, Kamal; Lodola, Alessio; Volta, Francesco; Viglioli, Martina; Ferlenghi, Francesca; Galvani, Francesca; Galetti, Maricla; Bonelli, Mara; Fumarola, Claudia; Cavazzoni, Andrea; Flammini, Lisa; Verzè, Michela; Minari, Roberta; Petronini, Pier Giorgio; Tiseo, Marcello; Mor, Marco; Alfieri, Roberta | |
| State of the art and perspectives in pediatric hepatocellular carcinoma | 1-gen-2023 | Digiacomo, Graziana; Serra, Roberta Pia; Turrini, Elena; Tiri, Alessandra; Cavazzoni, Andrea; Alfieri, Roberta; Bertolini, Patrizia | |
| PD-L1 OVEREXPRESSION INDUCES ANGIOGENIC CYTOKINE SECRETION AND ENDOTHELIAL CELL MIGRATION VIA STAT SIGNALLING. | 1-gen-2023 | Digiacomo, G.; Cavazzoni, A.; Volta, F.; Alfieri, R.; Petronini, P. G.; Tiseo, M. | |
| CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS | 1-gen-2023 | La Monica, S.; Galetti, M.; Alfieri, R.; Cavazzoni, A.; Fumarola, C.; De Forni, D.; Lori, F.; Petronini, P. G.; Bonelli, M. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile